| abstract |
Compounds of formula (I) wherein: Q is naphthyl, heterocyclic or heterobicyclic; R?1 and R2¿, when taken separately, are hydrogen, hydroxy, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenyl, heterocyclic or heterobicyclic; R?1 and R2¿, when taken together, form a carbocyclic, carbobicyclic, heterocyclic or heterobicyclic group; R3 is -(CH¿2)nCOR?4, tetrazolyl, alkyltetrazolyl, triazolyl, alkyltriazolyl, -(CH¿2?)nCH2OH, -SO2R?4, -SO¿2NR5R6 or -NHSO¿2R?7; R4 is hydrogen, hydroxy, -NR5R6, -NHSO¿2R?7, alkoxy, alkylthio, -NR5R6, -NHSO¿2R?7 or -OY; n is 0 to 5; Y is a pharmaceutically acceptable cation or a group hydrolyzable under physiological conditions; R?5 and R6¿, when taken separately, are hydrogen, alkyl, -CONRR, -COOR or -CO(C¿6?H5); R?5 and R6¿, when taken together, form an azacyclic ring; R7 is alkyl or phenyl; each R is hydrogen or alkyl and X is an azacyclic or azabicyclic group, inhibit angiotensin II in mammals and are useful in treating conditions such as hypertension, congestive heart failure and glaucoma and as the active ingredient in pharmaceutical compositions for treating such conditions. |